Johnson & Johnson: Arthritis, Juvenile trials
The registry lists 10 Arthritis, Juvenile studies with Johnson & Johnson as lead sponsor. 1 are open to participants now and 5 have results posted.
Phase 1 1Phase 3 5No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingNCT06663332Phase 3
- A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate TherapyCompletedNCT02277444Phase 3Results posted
- A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)TerminatedNCT01230827Phase 3Results posted
- Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee SystemCompletedNCT00487565Not applicableResults posted
- Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKACompletedNCT00289107Not applicableResults posted
- Randomized Fixed Bearing vs Mobile Bearing Cruciate Retaining TKACompletedNCT00289094Not applicableResults posted
- A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or PsoriasisCompletedNCT05252533Phase 1
- A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisCompletedNCT05083182Phase 3
- A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin AntibodiesWithdrawnNCT00210977
- A Study of the Safety and Effectiveness of Infliximab (Remicade) in Patients With Juvenile Rheumatoid ArthritisCompletedNCT00036374Phase 3